Scholarlink

<p>Around 5.3% of adults worldwide are living with metabolic dysfunction-associated steatohepatitis (MASH). As liver fibrosis develops, their incidence of cirrhosis, hepatocellular carcinoma, cardiovascular complications, and non-liver cancer increases. We analyse MAESTRO-NASH resmetirom data and discuss real-world implications following approval. US-based patients now have a novel treatment and expert use recommendations. We anticipate that the UK and EU will approve resmetirom; however, questions remain regarding patient selection and implementation practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月22日

查看全文
  • Paul N. Brennan,
  • Christopher J. Kopka,
  • Leire Agirre-Garrido,
  • Camila Dalby Hansen,
  • Naim Alkhouri,
  • Jörn M. Schattenberg,
  • Dana Ivancovsky-Wajcman,
  • Scott Isaacs,
  • Maurice Michel,
  • Jeffrey V. Lazarus

摘要

Around 5.3% of adults worldwide are living with metabolic dysfunction-associated steatohepatitis (MASH). As liver fibrosis develops, their incidence of cirrhosis, hepatocellular carcinoma, cardiovascular complications, and non-liver cancer increases. We analyse MAESTRO-NASH resmetirom data and discuss real-world implications following approval. US-based patients now have a novel treatment and expert use recommendations. We anticipate that the UK and EU will approve resmetirom; however, questions remain regarding patient selection and implementation practice.